Sherry X Yang

Sherry X Yang

UNVERIFIED PROFILE

Are you Sherry X Yang?   Register this Author

Register author
Sherry X Yang

Sherry X Yang

Publications by authors named "Sherry X Yang"

Are you Sherry X Yang?   Register this Author

36Publications

729Reads

43Profile Views

Multiple Grouped Scalp Nodules in a Middle-Aged Man: A Rare Case of Angiolymphoid Hyperplasia with Eosinophilia.

Skinmed 2018;16(1):71-72. Epub 2018 Feb 1.

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.

View Article

Download full-text PDF

Source
October 2019

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.

Breast Cancer Res Treat 2019 Jun 12;175(2):287-295. Epub 2019 Feb 12.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05142-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533413PMC
June 2019

Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer.

Theranostics 2017 22;7(4):945-951. Epub 2017 Feb 22.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.19102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381256PMC
October 2017

Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic.

Expert Opin Drug Discov 2016 Nov 25;11(11):1071-1080. Epub 2016 Sep 25.

a National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2016.1236785DOI Listing
November 2016

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Cancer Treat Rev 2016 Apr 9;45:87-96. Epub 2016 Mar 9.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.03.004DOI Listing
April 2016

Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach.

Chin Clin Oncol 2016 Feb;5(1)

37 Convent Drive, Bldg. 37/Rm.1048, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/9173/9877
Publisher Site
http://dx.doi.org/10.3978/j.issn.2304-3865.2016.01.02DOI Listing
February 2016

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

Cancer Chemother Pharmacol 2015 Dec 20;76(6):1273-83. Epub 2015 Oct 20.

The Children's Hospital of Philadelphia, The Perelman School of Medicine at The University of Pennsylvania, CTRB 4016, 3501 Civic Center Blvd, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2845-1DOI Listing
December 2015

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Nat Rev Clin Oncol 2015 Aug 7;12(8):445-64. Epub 2015 Apr 7.

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive MSC9739, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520755PMC
August 2015

Notch1 phenotype and clinical stage progression in non-small cell lung cancer.

J Hematol Oncol 2015 Feb 6;8. Epub 2015 Feb 6.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-014-0104-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343190PMC
February 2015

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

J Clin Endocrinol Metab 2014 Apr 1;99(4):1291-7. Epub 2014 Jan 1.

Medical Oncology Branch (C.O., M.E., M.V., J.W., S.B., T.F.), Center for Cancer Research, Laboratory of Pathology (S.P.), and National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis (S.X.Y., D.N.), National Cancer Institute, and Radiology and Imaging Sciences (A.M.V.), Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-2298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973787PMC
April 2014

Targeting notch signaling pathway in cancer: clinical development advances and challenges.

Pharmacol Ther 2014 Feb 27;141(2):140-9. Epub 2013 Sep 27.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2013.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982918PMC
February 2014

Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence.

Chin J Cancer Res 2012 Dec;24(4):257-8

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, USA.

View Article

Download full-text PDF

Source
http://www.cjcrcn.org/article/html_1107.html
Publisher Site
http://dx.doi.org/10.3978/j.issn.1000-9604.2012.09.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551324PMC
December 2012

Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

Clin Breast Cancer 2012 Aug 12;12(4):232-9. Epub 2012 Jun 12.

George Washington University School of Public Health and Health Services, Washington, DC 20037, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.04.005DOI Listing
August 2012

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.

Cell Cycle 2011 Dec 1;10(23):4074-82. Epub 2011 Dec 1.

Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.10.23.18170
Publisher Site
http://dx.doi.org/10.4161/cc.10.23.18170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272289PMC
December 2011

p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.

Int J Oncol 2011 May 9;38(5):1445-52. Epub 2011 Mar 9.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg. 37/Rm 1048, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2011.966DOI Listing
May 2011

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

J Clin Oncol 2010 Jun 17;28(18):2974-81. Epub 2010 May 17.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.26.1602
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.1602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903333PMC
June 2010

Bevacizumab and breast cancer: current therapeutic progress and future perspectives.

Authors:
Sherry X Yang

Expert Rev Anticancer Ther 2009 Dec;9(12):1715-25

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37/Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.09.153
Publisher Site
http://dx.doi.org/10.1586/era.09.153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819039PMC
December 2009

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.

Cancer Biol Ther 2009 Nov 25;8(21):2004-9. Epub 2009 Nov 25.

Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.8.21.9917DOI Listing
November 2009

Phase 0 clinical trials: conceptions and misconceptions.

Cancer J 2008 May-Jun;14(3):133-7

Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318172d6f3DOI Listing
September 2008

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.

Clin Cancer Res 2008 Sep;14(18):5893-9

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587275PMC
September 2008

Designing phase 0 cancer clinical trials.

Clin Cancer Res 2008 Jun;14(12):3675-82

Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-2440, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435428PMC
June 2008

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

J Proteome Res 2008 Apr 8;7(4):1508-17. Epub 2008 Feb 8.

Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr7008127DOI Listing
April 2008

PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors.

Cell Cycle 2008 Mar 9;7(6):818-29. Epub 2008 Jan 9.

Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.7.6.5597
Publisher Site
http://dx.doi.org/10.4161/cc.7.6.5597DOI Listing
March 2008

Circulating biomarkers of bevacizumab activity in patients with breast cancer.

Cancer Biol Ther 2008 Jan 21;7(1):15-20. Epub 2007 Nov 21.

Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.7.1.5337DOI Listing
January 2008

Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

J Clin Oncol 2007 Aug 2;25(23):3421-7. Epub 2007 Jul 2.

Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2006.10.0784
Publisher Site
http://dx.doi.org/10.1200/JCO.2006.10.0784DOI Listing
August 2007

Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray.

Oncol Rep 2007 Feb;17(2):281-7

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
February 2007

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Cancer Biol Ther 2006 Jan 22;5(1):22-7. Epub 2006 Jan 22.

Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.1.2349DOI Listing
January 2006

A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer.

Clin Breast Cancer 2005 Dec;6(5):460-3

Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2005.n.052DOI Listing
December 2005

Epidermal growth factor receptor expression in breast cancer.

J Clin Oncol 2005 Nov;23(31):8118-9; author reply 8119-20

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.03.0130DOI Listing
November 2005

Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.

Clin Cancer Res 2005 Sep;11(17):6226-32

Cancer Therapeutics Branch in Center for Cancer Research , National Cancer Institute, NIH, Bethesda, Maryland 20889, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0270DOI Listing
September 2005